Prestige Consumer Healthcare Inc(PBH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 13.07 | EPS (ttm) | 3.57 | Insider Own | 1.47% | Shs Outstand | 47.4M | Perf Week | -6.25% |
| Market Cap | 2.21B | Forward P/E | 9.09 | EPS next Y | 11.97% | Insider Trans | -0.32% | Shs Float | 46.7M | Perf Month | -9.15% |
| Enterprise Value | 4.19B | PEG | 1.33 | EPS next Q | 1.07 | Inst Own | 115.03% | Short Float | 9.82% | Perf Quarter | 0.02% |
| Income | 0.17B | P/S | 2 | EPS this Y | 4.66% | Inst Trans | 2.38% | Short Ratio | 8.04 | Perf Half Y | -23.36% |
| Sales | 1.10B | P/B | 1.15 | EPS next 5Y | 6.86% | ROA | 4.3% | Short Interest | 4.58M | Perf YTD | -24.33% |
| Book/sh | 40.46 | P/C | 24.81 | EPS past 3/5Y | - 3.72% | ROE | 9.12% | 52W High | -34.32% ($71.07) | Perf Year | -25.87% |
| Cash/sh | 1.88 | P/FCF | 9.4 | Sales past 3/5Y | -1.17% 2.91% | ROIC | 4.34% | 52W Low | 9.53% ($42.62) | Perf 3Y | -19.35% |
| Dividend Est. | - | EV/EBITDA | 12.99 | EPS Y/Y TTM | -16.45% | Gross Margin | 51.59% | Volatility(W/M) | 3.53% 2.81% | Perf 5Y | -13.2% |
| Dividend TTM | - | EV/Sales | 3.79 | Sales Y/Y TTM | -1.36% | Oper. Margin | 26.26% | ATR (14) | 1.68 | Perf 10Y | -0.06% |
| Dividend Ex-Date | 2013/12/27 | Quick Ratio | 1.99 | EPS Q/Q | -35.65% | Profit Margin | 15.57% | RSI (14) | 34.47 | Recom | 1.71 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.23 | Sales Q/Q | 6.48% | SMA20 | -7.8% ($50.63) | Beta | 0.34 | Target Price | $67.25 |
| Payout | - | Debt/Eq | 1.08 | Earnings | 2026/8/6 | SMA50 | -7.85% ($50.66) | Rel Volume | 1.35 | Prev Close | $47.62 |
| Employees | 890 | LT Debt/Eq | 1.07 | EPS/Sales Surpr. | 9.64% 5.01% | SMA200 | -17.34% ($56.47) | Avg Volume(3M) | 0.57M | Price | $46.68 |
| IPO | 2005/2/10 | Option/Short | Yes/Yes | Trades | 9630 | Volume | 767,157 | Change | -1.97% |
Company
PBH is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
This is a U.S. company that owns and sells over-the-counter (OTC) drugs and consumer health care brands. It operates a diverse portfolio of non-prescription health and wellness brands, generating stable revenue through well-known names spanning categories such as eye care, digestive health, feminine care, and pain relief. The company is a consumer health care operator that grows through brand acquisitions and marketing.
Over the past 1 year, on the lower side
34% below its 1-year high.
PBH makes money exceptionally well
26.26% of revenue is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +4.7% this year.
Tap to view numbers
The stock looks undervalued
Trading at 13.1 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -19.4% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 115.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
CCFE 0.07%
PJP 0.02%
SAEF 0.02%
CSMD 0.02%
XPH 0.01%It ranks #4 in the industry
Based on market cap of $2B.
PBH $2B PER 13.1
TAK $60B PER -
TEVA $46B PER 65.4
HLN $41B PER 19.0
FAQ
What kind of company is PBH?
PBH belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of PBH?
The market cap of PBH is approximately $2.2B, ranking 2,004 within its sector.
What is the P/E ratio of PBH?
PBH has a P/E ratio of approximately 13.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for PBH?
PBH has recorded a 52-week high of $71.07 and a low of $42.62.
